


LISTING OF CLAIMS

CLAIMS 1-16 (CANCELED) :

17. (NEW) A composition comprising a combination of a compound favouring lipid and carbohydrate metabolisms and an antioxidant agent.

18. (NEW) The composition of Claim 17, wherein the compound favouring lipid and carbohydrate metabolisms is a compound selected from those of formula (I) :



wherein :


• X represents oxygen or sulphur or CH₂ or $\begin{array}{c} R^2 \\ | \\ CH \end{array}$ (wherein R² together with R² forms an additional bond),

• R¹ and R², which may be identical or different, each represents hydrogen, linear or branched (C₁-C₆)alkyl, aryl, aryl-(C₁-C₆)alkyl in which the alkyl moiety may be linear or branched, aryloxy, aryl-(C₁-C₆)alkoxy in which the alkoxy moiety may be linear or branched, linear or branched (C₁-C₆)alkoxy, hydroxy, amino, linear or branched (C₁-C₆)alkylamino or dialkylamino in which the alkyl moieties are linear or branched (C₁-C₆),

or R¹ and R² together form oxo, thioxo or imino, and R² may also form with R² an additional bond,

- A represents a (C₁-C₆)alkylene chain in which a CH₂ group may be replaced by a hetero atom selected from oxygen and sulphur, by NR_a (wherein R_a represents hydrogen or linear or branched (C₁-C₆)alkyl), or by phenylene or naphthylene,
- B represents a linear or branched (C₁-C₆)alkyl group or a linear or branched (C₂-C₆)alkenyl group, those groups being substituted by an R⁵ group,

by a group of formula (II) : $\begin{array}{c} \text{R}^5 \\ \diagup \\ \text{---} \\ \diagdown \\ \text{R}^6 \end{array}$ (II) ., or by a group of formula (III) :



in which groups:

- the representation --- denotes that the bond is single or double,
 - R⁵ represents $\begin{array}{c} \text{C} - \text{Z}' \\ || \\ \text{Z} \end{array}$ wherein Z represents sulphur or oxygen and Z' represents
- OR or NRR',
- and R⁶ represents $\begin{array}{c} \text{C} - \text{Z}'' \\ || \\ \text{Z} \end{array}$ wherein Z'' represents Z' or R

(wherein R and R', which may be identical or different, each represents R'' or -C(Me)₂COOR'' wherein R'' represents hydrogen or linear or branched (C₁-C₆)alkyl, linear or branched (C₂-C₆)alkenyl, linear or branched (C₂-C₆)alkynyl, aryl, aryl-(C₁-C₆)alkyl in which the alkyl moiety may be linear or branched, aryl-(C₂-C₆)alkenyl in which the alkenyl moiety may be linear or branched, aryl-(C₂-C₆)alkynyl in which the alkynyl moiety may be linear or branched, heteroaryl, heteroaryl-(C₁-C₆)alkyl in which the alkyl moiety may be linear or branched, heteroaryl-(C₂-C₆)alkenyl in which the alkenyl moiety may be linear or branched, heteroaryl-(C₂-C₆)alkynyl in which the alkynyl moiety may be linear or branched, (C₃-C₈)cycloalkyl, (C₃-C₈)cycloalkyl-(C₁-C₆)alkyl in which the alkyl moiety may be linear or branched, or linear or branched (C₁-C₆)polyhaloalkyl),

- R^3 and R^4 , which may be identical or different, each represents hydrogen, halogen or R, OR or NRR' (wherein R and R' are as defined hereinbefore),
or R^3 and R^4 together with the carbon atoms carrying them, when they are carried by two adjacent carbon atoms, form a ring that has 5 or 6 ring members and that may contain a hetero atom selected from oxygen, sulphur and nitrogen,

- D represents:

a benzene nucleus, in which case X may not represent a group $\begin{array}{c} R'^2 \\ | \\ CH \end{array}$ as defined hereinbefore

or D represents a pyridine, pyrazine, pyrimidine or pyridazine nucleus,
those five nuclei being unsubstituted or substituted by from 1 to 3 identical or different

groups selected from R, OR, $S(O)_nR$, $C(Z)R$, $\begin{array}{c} OR \\ | \\ -CH-R' \end{array}$, $C(Z)OR$, NRR' , $C(Z)NRR'$,

$\begin{array}{c} R \\ | \\ -C=N-OR' \end{array}$, $\begin{array}{c} R \\ | \\ -N-C(Z)R' \end{array}$, $\begin{array}{c} R \\ | \\ -N-C(Z)OR' \end{array}$ (in which groups R, R' and Z are

as defined hereinbefore and n is 0, 1 or 2), cyano, nitro and halogen atoms,


it being understood that :

- * when A represents CH_2 , B may not represent linear or branched (C_1-C_6) alkyl substituted

by $\begin{array}{c} -C-NRR' \\ || \\ Z \end{array}$,

- * when A and B are in the ortho position in relation to one another on the benzene nucleus carrying them, B may not represent linear or branched (C_2-C_6) -alkenylene

substituted by $\begin{array}{c} -C-Z' \\ || \\ O \end{array}$,

- * when A represents $-CH_2-$ , B may not represent $-CH_2-COOH$,

- * aryl may be a phenyl, naphthyl or biphenyl group, which groups may be partially hydrogenated,
- * heteroaryl may be any mono- or bi-cyclic aromatic group containing from 5 to 10 ring members, which may be partially hydrogenated on one of the rings in the case of bicyclic heteroaryls, and which contains from 1 to 3 hetero atoms selected from oxygen, nitrogen and sulphur,

wherein the aryl and heteroaryl groups may be substituted by from 1 to 3 groups selected from linear or branched (C₁-C₆)alkyl, linear or branched (C₁-C₆)alkoxy, carboxy, formyl, NR_bR_c (wherein R_b and R_c, which may be identical or different, each represents hydrogen, linear or branched (C₁-C₆)alkyl, aryl or heteroaryl), ester, amido, nitro, cyano, O-C(Me)₂COOR" (wherein R" is as defined hereinbefore) and halogen,

its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

19. (NEW) The composition of Claim 17, wherein the compound favouring lipid and carbohydrate metabolisms is dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]benzyl}malonate, its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.

20. (NEW) The composition of Claim 17, wherein the antioxidant agent is coenzyme Q₁₀.

21. (NEW) The composition of Claim 17, wherein the antioxidant agent is vitamin E.

22. (NEW) The composition of Claim 17, which is a combination of dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]benzyl}malonate and coenzyme Q₁₀.

23. (NEW) The composition of Claim 17, which is a combination of dimethyl 2-{4-[2-(6-benzoyl-2-oxo-1,3-benzothiazol-3(2*H*)-yl)ethoxy]benzyl}malonate and vitamin E.

24. (NEW) A pharmaceutical composition comprising as active ingredient a composition of Claim 17, in combination with one or more pharmaceutically acceptable excipients.

25. (NEW) A method for treating and/or preventing a living animal body, including a human, afflicted with obesity comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of obesity.

26. (NEW) A method for treating and/or preventing a living animal body, including a human afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of the condition.

27. (NEW) A method for treating and/or preventing a living animal body, including a human, afflicted with obesity caused by a therapeutic treatment, comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of obesity caused by a therapeutic treatment.

28. (NEW) A method for treating and/or preventing a living animal body, including a human, afflicted with obesity caused by treatment for type I or II diabetes, comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of obesity caused by treatment for type I or II diabetes.

29. (NEW) A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by a therapeutic treatment, comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of the condition.

30. (NEW) A method for treating and/or preventing a living animal body, including a human, afflicted with an overweight condition characterised by a body mass index greater than 25 and less than 30 caused by treatment for type I or II diabetes comprising the step of administering to the living animal body, including a human, an amount of a composition of Claim 17 which is effective for alleviation of the condition.